BBP-398 Clinical Trials (2026): 5 Studies for Non Small Cell Lung Cancer & Advanced Solid Tumor
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
5 BBP-398 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 5 indications (including Non Small Cell Lung Cancer & Advanced Solid Tumor) and 132 total planned enrollment. Most recent activity: NCT05480865 (Aug 2024).
BBP-398 clinical trials at a glance: phase × recruitment status
| Phase | terminated | Total |
|---|---|---|
| P1 | 5 | 5 |
BBP-398 clinical trials by indication
NSCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06032936 | — | P1 | terminated | BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations |
Non Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05375084 | — | P1 | terminated | SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation |
Advanced Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05621525 | — | P1 | terminated | Phase I Study of the BBP-398 in Patients With Advance Solid Tumors |
Solid Tumor, Adult (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05480865 | Argonaut | P1 | terminated | SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation |
Tumor, Solid (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04528836 | — | P1 | terminated | First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors |
Terminated and withdrawn BBP-398 trials (5)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05480865terminatedSHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation
- NCT04528836terminatedFirst-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors
- NCT05375084terminatedSHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation
- NCT06032936terminatedBBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations
- NCT05621525terminatedPhase I Study of the BBP-398 in Patients With Advance Solid Tumors
All BBP-398 trials (5)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05480865 | Argonaut | SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation | P1 | terminated | 28 | Navire Pharma Inc., a BridgeBio company | Jul 2022 |
| NCT04528836 | First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors | P1 | terminated | 72 | Navire Pharma Inc., a BridgeBio company | Nov 2020 | |
| NCT05375084 | SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation | P1 | terminated | 21 | Navire Pharma Inc., a BridgeBio company | Oct 2022 | |
| NCT06032936 | BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations | P1 | terminated | 4 | LianBio LLC | Jul 2023 | |
| NCT05621525 | Phase I Study of the BBP-398 in Patients With Advance Solid Tumors | P1 | terminated | 7 | LianBio LLC | Oct 2022 |
BBP-398 clinical trials: frequently asked questions
- How many BBP-398 clinical trials are there?
- 5 BBP-398 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov.
- Are BBP-398 clinical trials recruiting in 2026?
- No active BBP-398 trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is BBP-398 being studied for?
- BBP-398 is being studied for Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic NSCLC, Metastatic Solid Tumor, NSCLC and 4 more. The trials are grouped by indication on this page.
- What phase is BBP-398 in?
- BBP-398 clinical trials span 5 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors BBP-398 clinical trials?
- The lead sponsor across the most BBP-398 trials is Navire Pharma Inc., a BridgeBio company, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming BBP-398as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: